Rhabdomyolysis asociated with naltrexone

Sina Zaim, David B. Wiley, Shirley Albano-Aluquin

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

OBJECTIVE: to report a possible association between naltrexone therapy and the development of rhabdomyolysis in one patient. CASE SUMMARY: A 28- year-old white man in good physical health was started on naltrexone 50 mg/d for inpatient treatment of alcohol dependence and depression. A routine serum chemistry panel obtained on day 9 of naltrexone therapy showed marked new elevations in creatine kinase and aspartate aminotransferase. The patient remained asymptomatic and did not develop renal insufficiency. The serum enzyme concentrations returned to normal within eight days of naltrexone discontinuation. DISCUSSION: Rhabdomyolysis has not been previously reported to occur in patients during treatment with naltrexone. Alcoholism may result in a reversible acute muscle syndrome, but our patient did not fit the appropriate clinical profile for such a syndrome. Additionally, the other prescribed medications could not be implicated as possible causative agents. CONCLUSIONS: This case report illustrates a possible association between naltrexone therapy and rhabdomyolysis.

Original languageEnglish (US)
Pages (from-to)312-313
Number of pages2
JournalAnnals of Pharmacotherapy
Volume33
Issue number3
DOIs
StatePublished - Apr 14 1999

Fingerprint

Naltrexone
Rhabdomyolysis
Alcoholism
Therapeutics
Creatine Kinase
Aspartate Aminotransferases
Serum
Renal Insufficiency
Inpatients
Depression
Muscles
Health
Enzymes

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)

Cite this

Zaim, Sina ; Wiley, David B. ; Albano-Aluquin, Shirley. / Rhabdomyolysis asociated with naltrexone. In: Annals of Pharmacotherapy. 1999 ; Vol. 33, No. 3. pp. 312-313.
@article{c7653c7b5abe414b8763783dc67f6889,
title = "Rhabdomyolysis asociated with naltrexone",
abstract = "OBJECTIVE: to report a possible association between naltrexone therapy and the development of rhabdomyolysis in one patient. CASE SUMMARY: A 28- year-old white man in good physical health was started on naltrexone 50 mg/d for inpatient treatment of alcohol dependence and depression. A routine serum chemistry panel obtained on day 9 of naltrexone therapy showed marked new elevations in creatine kinase and aspartate aminotransferase. The patient remained asymptomatic and did not develop renal insufficiency. The serum enzyme concentrations returned to normal within eight days of naltrexone discontinuation. DISCUSSION: Rhabdomyolysis has not been previously reported to occur in patients during treatment with naltrexone. Alcoholism may result in a reversible acute muscle syndrome, but our patient did not fit the appropriate clinical profile for such a syndrome. Additionally, the other prescribed medications could not be implicated as possible causative agents. CONCLUSIONS: This case report illustrates a possible association between naltrexone therapy and rhabdomyolysis.",
author = "Sina Zaim and Wiley, {David B.} and Shirley Albano-Aluquin",
year = "1999",
month = "4",
day = "14",
doi = "10.1345/aph.18214",
language = "English (US)",
volume = "33",
pages = "312--313",
journal = "Annals of Pharmacotherapy",
issn = "1060-0280",
publisher = "Harvey Whitney Books Company",
number = "3",

}

Rhabdomyolysis asociated with naltrexone. / Zaim, Sina; Wiley, David B.; Albano-Aluquin, Shirley.

In: Annals of Pharmacotherapy, Vol. 33, No. 3, 14.04.1999, p. 312-313.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Rhabdomyolysis asociated with naltrexone

AU - Zaim, Sina

AU - Wiley, David B.

AU - Albano-Aluquin, Shirley

PY - 1999/4/14

Y1 - 1999/4/14

N2 - OBJECTIVE: to report a possible association between naltrexone therapy and the development of rhabdomyolysis in one patient. CASE SUMMARY: A 28- year-old white man in good physical health was started on naltrexone 50 mg/d for inpatient treatment of alcohol dependence and depression. A routine serum chemistry panel obtained on day 9 of naltrexone therapy showed marked new elevations in creatine kinase and aspartate aminotransferase. The patient remained asymptomatic and did not develop renal insufficiency. The serum enzyme concentrations returned to normal within eight days of naltrexone discontinuation. DISCUSSION: Rhabdomyolysis has not been previously reported to occur in patients during treatment with naltrexone. Alcoholism may result in a reversible acute muscle syndrome, but our patient did not fit the appropriate clinical profile for such a syndrome. Additionally, the other prescribed medications could not be implicated as possible causative agents. CONCLUSIONS: This case report illustrates a possible association between naltrexone therapy and rhabdomyolysis.

AB - OBJECTIVE: to report a possible association between naltrexone therapy and the development of rhabdomyolysis in one patient. CASE SUMMARY: A 28- year-old white man in good physical health was started on naltrexone 50 mg/d for inpatient treatment of alcohol dependence and depression. A routine serum chemistry panel obtained on day 9 of naltrexone therapy showed marked new elevations in creatine kinase and aspartate aminotransferase. The patient remained asymptomatic and did not develop renal insufficiency. The serum enzyme concentrations returned to normal within eight days of naltrexone discontinuation. DISCUSSION: Rhabdomyolysis has not been previously reported to occur in patients during treatment with naltrexone. Alcoholism may result in a reversible acute muscle syndrome, but our patient did not fit the appropriate clinical profile for such a syndrome. Additionally, the other prescribed medications could not be implicated as possible causative agents. CONCLUSIONS: This case report illustrates a possible association between naltrexone therapy and rhabdomyolysis.

UR - http://www.scopus.com/inward/record.url?scp=0032588068&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032588068&partnerID=8YFLogxK

U2 - 10.1345/aph.18214

DO - 10.1345/aph.18214

M3 - Article

VL - 33

SP - 312

EP - 313

JO - Annals of Pharmacotherapy

JF - Annals of Pharmacotherapy

SN - 1060-0280

IS - 3

ER -